Conference abstractPublished 13 Mar 2017
Nanoparticles for oral delivery of Insulin: Facts and safety concerns
University of Coimbra, Portugal
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nanotechnology-based approaches towards an oral delivery of macromolecules such as insulin are increasingly therapeutic approaches towards the prevention or treatment of diabetes. Nanoencapsulation of insulin increases its protection against enzymatic degradation, and facilitates its absorption through intestinal membranes. However, the intestinal absorption of insulin nanoparticles may be related to a stimulatory reaction induced by the local mucosa immune system. Intestinal epithelium is an immune privileged organ capable of mediating immune reactions either playing a local protective role or by triggering an inflammatory response to the presence of nanoparticles. Compromising safety of insulin delivered by nanoparticles, by inadequacy or insufficiency of studies, may lead to exacerbation of the inflammatory pathways conducive to unwanted local and other severe adverse effects. Therefore, it is imperative to include comprehensive safety assays in early pre-clinical studies in order to increase the representativeness of the results and strengthen the potential of oral delivery of insulin by means of nanoparticles. Herein, focus will be put on recent reports in oral delivery of insulin nanoparticles for diabetes as well a critical analysis of the safety studies supporting their pre-clinical development. The improvement of early safety assessment by transitioning to quantitative, nanoparticle composition-immune performance relationship studies in representative models will also be elucidated. Thereby, the role and importance of rational optimization in the development of “safe by design” insulin nanoparticles will be contextualized in the field of diabetes..
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNanotechnology
- SubjectDentistry & Oral Health
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “António José Ribeiro”